Podimo ApS develops a platform, which provides podcast streaming and download services. The company provides audio content to the users. Podimo ApS was founded in 2019 and is headquartered in Copenhagen, Denmark.
Corti is an artificial intelligence platform designed to assist emergency medical dispatchers and healthcare providers in making critical, life-saving decisions. The platform focuses on medical triaging, aiming to reduce errors and enhance the accuracy of human decision-making. By employing advanced speech recognition and natural language processing, Corti analyzes patient interviews and prepares case files prior to consultations. It also suggests relevant questions to ask, enabling healthcare professionals to understand patient situations more effectively. Through these capabilities, Corti aims to improve the speed and accuracy of decision-making in emergency medical contexts, ultimately contributing to better patient outcomes.
Kobaj operates an online marketplace focused on the buying and selling of wine, connecting winemakers directly with customers across Europe. The platform enables winemakers to showcase their products and offers customers access to competitive pricing typically reserved for importers and wine merchants. In addition to facilitating sales, Kobaj provides a range of services including co-buying, beverage manufacturing, payment processing, insurance, and logistics for the transportation of goods. This comprehensive approach enhances the e-commerce experience for both sellers and buyers in the wine industry.
Layerise ApS, founded in 2019 and based in Copenhagen, Denmark, specializes in developing product onboarding software that enhances customer experiences. The company offers a comprehensive platform that includes features such as product reminders, how-to guides, customer insights, and smart localization. By focusing on interactive customer engagement rather than traditional product manuals, Layerise enables brands to provide effective onboarding, facilitate one-tap product registrations, and create content-rich experiences. Its tools also support post-sale marketing and customer assistance, helping clients improve service quality and transform average sales into positive customer experiences.
Forecast ApS is a software development company based in Copenhagen, Denmark, that specializes in project management solutions. Founded in 2016, Forecast provides a comprehensive platform designed to help professional service organizations streamline their project and resource management. The software integrates various functionalities, including financial management, time tracking, team collaboration, and business intelligence, all powered by artificial intelligence. This intelligent platform enables users to plan, budget, and predict project outcomes effectively. By unifying project-related data, Forecast facilitates better decision-making and enhances operational efficiency, allowing teams to focus on innovation rather than administrative tasks. The company aims to shift the project management paradigm from a project-first approach to a client-first strategy, ultimately delivering improved results for businesses.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Layerise ApS, founded in 2019 and based in Copenhagen, Denmark, specializes in developing product onboarding software that enhances customer experiences. The company offers a comprehensive platform that includes features such as product reminders, how-to guides, customer insights, and smart localization. By focusing on interactive customer engagement rather than traditional product manuals, Layerise enables brands to provide effective onboarding, facilitate one-tap product registrations, and create content-rich experiences. Its tools also support post-sale marketing and customer assistance, helping clients improve service quality and transform average sales into positive customer experiences.
SoundBoks is a Copenhagen-based hardware start-up developing and selling battery-powered speaker.
Founded in January 2015, the company developed a shock and weatherproof design that is portable and durable, with up to 60 hours of battery life at loud volume. It also combines high SPL speaker units with a powerful amplifier in order to reach sounds with an output as high as 119db.
Finematter Aps is an online fine jewelry store founded in 2020 and based in Copenhagen, Denmark. The company operates an e-commerce platform designed to facilitate the sale of fine jewelry, showcasing locally handcrafted designer pieces, gold and silver goods, and watches. By allowing small independent jewelers to sell their creations directly to consumers, Finematter minimizes third-party retail overheads and emphasizes the unique qualities of handcrafted items. This approach not only supports local artisans but also provides consumers with access to distinctive jewelry that celebrates individuality.
Podimo ApS develops a platform, which provides podcast streaming and download services. The company provides audio content to the users. Podimo ApS was founded in 2019 and is headquartered in Copenhagen, Denmark.
BLAST Premier is an esports entertainment company that specializes in broadcast studio shows, arena events, and online content.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Forecast ApS is a software development company based in Copenhagen, Denmark, that specializes in project management solutions. Founded in 2016, Forecast provides a comprehensive platform designed to help professional service organizations streamline their project and resource management. The software integrates various functionalities, including financial management, time tracking, team collaboration, and business intelligence, all powered by artificial intelligence. This intelligent platform enables users to plan, budget, and predict project outcomes effectively. By unifying project-related data, Forecast facilitates better decision-making and enhances operational efficiency, allowing teams to focus on innovation rather than administrative tasks. The company aims to shift the project management paradigm from a project-first approach to a client-first strategy, ultimately delivering improved results for businesses.
Astralis is a Copenhagen-based professional e-sports organization recognized for its competitive teams, particularly in Counter-Strike, where it ranks among the top teams worldwide. Founded by Frederik Byskov and Jacob Lund Kristensen, along with five prominent players from the Counter-Strike team, Astralis has established itself as a significant player in the global esports industry. The organization not only operates its Counter-Strike team but also manages teams in League of Legends and FIFA, focusing on developing strong sports and entertainment brands. Astralis engages in media partnerships and channels to enhance its brand presence and connect with fans and audiences worldwide.
Podimo ApS develops a platform, which provides podcast streaming and download services. The company provides audio content to the users. Podimo ApS was founded in 2019 and is headquartered in Copenhagen, Denmark.
Peakon ApS, founded in 2008 and based in Copenhagen, Denmark, specializes in real-time people analytics aimed at enhancing employee engagement and retention. The Peakon platform automatically gathers employee feedback and analyzes it to provide actionable insights for organizations. It supports a diverse range of users by being available in over 50 languages and can accommodate complex organizational structures with tens of thousands of employees. Feedback can be submitted through various channels, including web, mobile browsers, SMS, kiosks, and a native app, enabling organizations to foster an environment where employees can reach their full potential.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
RFRSH ApS is an esports marketing and media rights company based in Copenhagen, Denmark, founded in 2016. The company specializes in developing commercial and marketing strategies for esports teams, particularly focusing on the popular game Counter-Strike. RFRSH ApS collaborates with a range of established organizations and emerging player-owned teams to enhance their brand visibility and sports performance. By representing the commercial and media rights of these teams, RFRSH connects them with leading global brands for sponsorship and marketing agreements, thereby facilitating their growth and success in the competitive esports landscape.
Templafy ApS is a B2B Software-as-a-Service company specializing in template and document management solutions. Founded in 2013 and headquartered in Copenhagen, Denmark, Templafy offers a comprehensive platform that enhances productivity, branding, and compliance across various business documents, presentations, and emails. Its services include template and content accessibility, dynamic personalization, document automation, and brand validation, catering primarily to sectors such as banking, finance, consulting, education, insurance, consumer goods, and legal services. With a user base exceeding 1.5 million, Templafy streamlines the document creation workflow, allowing communication and compliance teams to maintain control while ensuring an enjoyable user experience for employees. The company has expanded its presence internationally, with offices in the United States, Germany, the Netherlands, the United Kingdom, Singapore, Hong Kong, Australia, New Zealand, and Spain, serving a diverse range of enterprise customers globally.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Grandhood is an investment management company based in Copenhagen, Denmark, founded in 2016. It focuses on retirement planning and pension services, aiming to make pension investments more transparent and accessible. The company has developed an online application that enables employers to facilitate retirement planning for their employees. This platform offers various features, including voluntary health insurance and coverage for reduced working capacity, death, and critical illnesses. By providing these services, Grandhood assists small businesses in supporting their employees' retirement readiness.
Private Equity Round in 2018
Blackwood Seven A/S is a Copenhagen-based company that offers an automated media allocation platform designed to enhance the effectiveness of advertising campaigns across various media channels, both online and offline. Founded in 2013, it specializes in video and audio media investments for dynamic businesses. The company employs predictive analytics, utilizing machine learning and artificial intelligence, to optimize media spending and improve return on investment by 15-25%. Its cloud-based platform allows for real-time modeling and comprehensive evaluation of marketing efforts, providing insights into the impact of historical spending and the effectiveness of different media channels. Blackwood Seven has additional locations in Munich, Los Angeles, New York, and Barcelona, serving a diverse clientele looking to maximize their media investments.
Forecast ApS is a software development company based in Copenhagen, Denmark, that specializes in project management solutions. Founded in 2016, Forecast provides a comprehensive platform designed to help professional service organizations streamline their project and resource management. The software integrates various functionalities, including financial management, time tracking, team collaboration, and business intelligence, all powered by artificial intelligence. This intelligent platform enables users to plan, budget, and predict project outcomes effectively. By unifying project-related data, Forecast facilitates better decision-making and enhances operational efficiency, allowing teams to focus on innovation rather than administrative tasks. The company aims to shift the project management paradigm from a project-first approach to a client-first strategy, ultimately delivering improved results for businesses.
Corti is an artificial intelligence platform designed to assist emergency medical dispatchers and healthcare providers in making critical, life-saving decisions. The platform focuses on medical triaging, aiming to reduce errors and enhance the accuracy of human decision-making. By employing advanced speech recognition and natural language processing, Corti analyzes patient interviews and prepares case files prior to consultations. It also suggests relevant questions to ask, enabling healthcare professionals to understand patient situations more effectively. Through these capabilities, Corti aims to improve the speed and accuracy of decision-making in emergency medical contexts, ultimately contributing to better patient outcomes.
Peakon ApS, founded in 2008 and based in Copenhagen, Denmark, specializes in real-time people analytics aimed at enhancing employee engagement and retention. The Peakon platform automatically gathers employee feedback and analyzes it to provide actionable insights for organizations. It supports a diverse range of users by being available in over 50 languages and can accommodate complex organizational structures with tens of thousands of employees. Feedback can be submitted through various channels, including web, mobile browsers, SMS, kiosks, and a native app, enabling organizations to foster an environment where employees can reach their full potential.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
RFRSH ApS is an esports marketing and media rights company based in Copenhagen, Denmark, founded in 2016. The company specializes in developing commercial and marketing strategies for esports teams, particularly focusing on the popular game Counter-Strike. RFRSH ApS collaborates with a range of established organizations and emerging player-owned teams to enhance their brand visibility and sports performance. By representing the commercial and media rights of these teams, RFRSH connects them with leading global brands for sponsorship and marketing agreements, thereby facilitating their growth and success in the competitive esports landscape.
Peakon ApS, founded in 2008 and based in Copenhagen, Denmark, specializes in real-time people analytics aimed at enhancing employee engagement and retention. The Peakon platform automatically gathers employee feedback and analyzes it to provide actionable insights for organizations. It supports a diverse range of users by being available in over 50 languages and can accommodate complex organizational structures with tens of thousands of employees. Feedback can be submitted through various channels, including web, mobile browsers, SMS, kiosks, and a native app, enabling organizations to foster an environment where employees can reach their full potential.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Freespee AB is a technology company specializing in call monetization solutions for the performance advertising sector, primarily operating in Europe and North America. Founded in 2008 and headquartered in Uppsala, Sweden, with additional offices in Helsinki, Copenhagen, and Berlin, Freespee provides various products aimed at enhancing communication and marketing efforts. Its offerings include Freespee Performance, which allows publishers and advertising networks to monetize phone calls generated from their media properties, and Freespee Analytics, a comprehensive tool for tracking leads and analyzing call data. Additionally, the Freespee Mobile Tracking SDK assists app developers in understanding consumer engagement through phone calls. By integrating multiple data sources, Freespee aims to facilitate personalized interactions between brands and their customers, thereby improving the overall consumer experience.
Blackwood Seven A/S is a Copenhagen-based company that offers an automated media allocation platform designed to enhance the effectiveness of advertising campaigns across various media channels, both online and offline. Founded in 2013, it specializes in video and audio media investments for dynamic businesses. The company employs predictive analytics, utilizing machine learning and artificial intelligence, to optimize media spending and improve return on investment by 15-25%. Its cloud-based platform allows for real-time modeling and comprehensive evaluation of marketing efforts, providing insights into the impact of historical spending and the effectiveness of different media channels. Blackwood Seven has additional locations in Munich, Los Angeles, New York, and Barcelona, serving a diverse clientele looking to maximize their media investments.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
Corti is an artificial intelligence platform designed to assist emergency medical dispatchers and healthcare providers in making critical, life-saving decisions. The platform focuses on medical triaging, aiming to reduce errors and enhance the accuracy of human decision-making. By employing advanced speech recognition and natural language processing, Corti analyzes patient interviews and prepares case files prior to consultations. It also suggests relevant questions to ask, enabling healthcare professionals to understand patient situations more effectively. Through these capabilities, Corti aims to improve the speed and accuracy of decision-making in emergency medical contexts, ultimately contributing to better patient outcomes.
Peakon ApS, founded in 2008 and based in Copenhagen, Denmark, specializes in real-time people analytics aimed at enhancing employee engagement and retention. The Peakon platform automatically gathers employee feedback and analyzes it to provide actionable insights for organizations. It supports a diverse range of users by being available in over 50 languages and can accommodate complex organizational structures with tens of thousands of employees. Feedback can be submitted through various channels, including web, mobile browsers, SMS, kiosks, and a native app, enabling organizations to foster an environment where employees can reach their full potential.
Astralis is a Copenhagen-based professional e-sports organization recognized for its competitive teams, particularly in Counter-Strike, where it ranks among the top teams worldwide. Founded by Frederik Byskov and Jacob Lund Kristensen, along with five prominent players from the Counter-Strike team, Astralis has established itself as a significant player in the global esports industry. The organization not only operates its Counter-Strike team but also manages teams in League of Legends and FIFA, focusing on developing strong sports and entertainment brands. Astralis engages in media partnerships and channels to enhance its brand presence and connect with fans and audiences worldwide.
Templafy ApS is a B2B Software-as-a-Service company specializing in template and document management solutions. Founded in 2013 and headquartered in Copenhagen, Denmark, Templafy offers a comprehensive platform that enhances productivity, branding, and compliance across various business documents, presentations, and emails. Its services include template and content accessibility, dynamic personalization, document automation, and brand validation, catering primarily to sectors such as banking, finance, consulting, education, insurance, consumer goods, and legal services. With a user base exceeding 1.5 million, Templafy streamlines the document creation workflow, allowing communication and compliance teams to maintain control while ensuring an enjoyable user experience for employees. The company has expanded its presence internationally, with offices in the United States, Germany, the Netherlands, the United Kingdom, Singapore, Hong Kong, Australia, New Zealand, and Spain, serving a diverse range of enterprise customers globally.
Blackwood Seven A/S is a Copenhagen-based company that offers an automated media allocation platform designed to enhance the effectiveness of advertising campaigns across various media channels, both online and offline. Founded in 2013, it specializes in video and audio media investments for dynamic businesses. The company employs predictive analytics, utilizing machine learning and artificial intelligence, to optimize media spending and improve return on investment by 15-25%. Its cloud-based platform allows for real-time modeling and comprehensive evaluation of marketing efforts, providing insights into the impact of historical spending and the effectiveness of different media channels. Blackwood Seven has additional locations in Munich, Los Angeles, New York, and Barcelona, serving a diverse clientele looking to maximize their media investments.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Issuu, Inc. is a digital publishing and discovery platform founded in 2006 in Copenhagen, Denmark. It provides a range of solutions that allow users to create, publish, and share digital publications such as magazines, catalogs, and corporate literature. The platform hosts over 17 million publications and attracts more than 80 million active readers monthly, delivering approximately 5.5 billion page views. Issuu's offerings include tools for custom viewer themes, API integrations for managing content, and monetization solutions through Issuu Story Cloud. The platform is designed to enhance the reading experience by transforming PDFs and images into visually appealing formats accessible across various devices and social media. With additional offices in Palo Alto, California, and Berlin, Germany, Issuu serves a diverse audience, including designers, developers, publishers, and advertisers, ultimately aiming to democratize the publishing experience while preserving the essence of print media.
Templafy ApS is a B2B Software-as-a-Service company specializing in template and document management solutions. Founded in 2013 and headquartered in Copenhagen, Denmark, Templafy offers a comprehensive platform that enhances productivity, branding, and compliance across various business documents, presentations, and emails. Its services include template and content accessibility, dynamic personalization, document automation, and brand validation, catering primarily to sectors such as banking, finance, consulting, education, insurance, consumer goods, and legal services. With a user base exceeding 1.5 million, Templafy streamlines the document creation workflow, allowing communication and compliance teams to maintain control while ensuring an enjoyable user experience for employees. The company has expanded its presence internationally, with offices in the United States, Germany, the Netherlands, the United Kingdom, Singapore, Hong Kong, Australia, New Zealand, and Spain, serving a diverse range of enterprise customers globally.
In 2013, the company's first spinal fusion implant in the Statur product line received CE mark. At the same time, the company was ISO 13485 certified demonstrating its adherence to the highest quality standards. With these accomplishments, the company is now ready to be introduced on the European and Canadian markets.
In early 2005, FBC Device was founded. With initial financial support in place, FBC Device was established and initial patents filed in late 2005. In December 2010, the European patent was granted and further funding raised, and in 2011 the US patent was granted.
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
addwish is a provider of wish list services for both consumers and online shops. Consumers can easily create wishlists to share with their family and friends. The highly intuitive interface on both addwish.com and on its iOS and Android mobile apps makes gift giving easier than ever before. For online retailers, addwish supplies a webshop plugin that enables the addwish functionality directly on their websites. As added benefit for the merchants, addwish promotes and suggests the products from their webshops to its users, resulting in traffic and lead generation.
Galecto, Inc. is a clinical-stage biotechnology company founded in 2011, focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company leverages over a decade of research on the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic processes. Its therapeutic approach includes small-molecule inhibitors targeting these proteins. Galecto's leading product candidate, GB0139, is aimed at treating severe fibrotic lung diseases, notably idiopathic pulmonary fibrosis, while another candidate, GB1211, is a selective oral galectin-3 inhibitor intended for managing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto is positioned to address critical unmet medical needs in the treatment of fibrotic and related diseases.
Blackwood Seven A/S is a Copenhagen-based company that offers an automated media allocation platform designed to enhance the effectiveness of advertising campaigns across various media channels, both online and offline. Founded in 2013, it specializes in video and audio media investments for dynamic businesses. The company employs predictive analytics, utilizing machine learning and artificial intelligence, to optimize media spending and improve return on investment by 15-25%. Its cloud-based platform allows for real-time modeling and comprehensive evaluation of marketing efforts, providing insights into the impact of historical spending and the effectiveness of different media channels. Blackwood Seven has additional locations in Munich, Los Angeles, New York, and Barcelona, serving a diverse clientele looking to maximize their media investments.
Mofibo, founded in Copenhagen in 2013, operates as one of the pioneering book subscription services globally. The company provides access to e-books through a proprietary platform, allowing consumers to enjoy a wide selection of titles for a monthly subscription fee. Currently available in three countries, Mofibo aims to expand its reach into additional markets within the next year. The company focuses on transforming the reading experience by employing a data-driven and customer-centric approach, seeking to enhance how millions of people engage with books.
Freespee AB is a technology company specializing in call monetization solutions for the performance advertising sector, primarily operating in Europe and North America. Founded in 2008 and headquartered in Uppsala, Sweden, with additional offices in Helsinki, Copenhagen, and Berlin, Freespee provides various products aimed at enhancing communication and marketing efforts. Its offerings include Freespee Performance, which allows publishers and advertising networks to monetize phone calls generated from their media properties, and Freespee Analytics, a comprehensive tool for tracking leads and analyzing call data. Additionally, the Freespee Mobile Tracking SDK assists app developers in understanding consumer engagement through phone calls. By integrating multiple data sources, Freespee aims to facilitate personalized interactions between brands and their customers, thereby improving the overall consumer experience.
Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.
Nuevolution A/S is a biopharmaceutical company based in Copenhagen, Denmark, founded in 2001. The company specializes in developing drug treatments for oncology and chronic inflammatory diseases. Nuevolution has created Chemetics®, an innovative drug discovery platform that combines wet chemistry and molecular biology to facilitate the rapid synthesis and screening of over one billion small molecule compounds. This technology allows for the efficient identification of potent drug candidates. The company's pipeline includes several programs such as ROR?t inhibitors and IL-17A inhibitors aimed at treating various diseases. Nuevolution collaborates with major pharmaceutical and biotechnology companies, entering into agreements with firms like Amgen and GlaxoSmithKline. Additionally, the company engages in contract research services, contributing to its revenue generation across multiple markets including Denmark, Sweden, and the USA. As a privately owned entity, Nuevolution is supported by key Scandinavian investors.
Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011, focused on developing and commercializing innovative antibiotics to address multi-drug resistant bacterial infections. The company specializes in solutions for hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Its lead product, Arenicin, is a non-toxic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against gram-negative pathogens. Adenium Biotech employs a semi-virtual model, leveraging a small team of experts and an international scientific advisory board to advance the Arenicin program through clinical development towards regulatory approval. The company's goal is to provide effective treatments for infections that are increasingly difficult to manage due to antibiotic resistance.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Orphazyme A/S is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing therapies for neurodegenerative orphan diseases, particularly those linked to protein misfolding such as lysosomal storage diseases. Founded in 2009, the company is focused on its lead candidate, Arimoclomol, which is undergoing clinical trials for multiple orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. Orphazyme’s research is grounded in academic discoveries from its founders at the Danish Cancer Society, and the company has established collaborations with leading academic institutions in Europe and the United States. In addition, Orphazyme has entered a strategic partnership with CombiGene AB to enhance its research and development efforts in the biopharmaceutical sector.
Podio ApS is a collaborative work platform based in Copenhagen, Denmark, that allows organizations to manage their workflows more effectively. Founded in 2007, Podio provides users with tools to share files, manage tasks, and create custom applications, enabling a tailored work environment. The platform integrates various functionalities, including messaging, reporting, and workflow management, to streamline work processes and reduce reliance on multiple disparate tools. Accessible via desktop and mobile applications, Podio enables real-time collaboration among team members. Since becoming a subsidiary of Citrix Systems, Podio has garnered a global user base, supporting diverse teams and organizations in optimizing their work activities.
Acarix A/S is a medical device company based in Kongens Lyngby, Denmark, specializing in the non-invasive detection of coronary artery disease (CAD). Founded in 2009, Acarix developed the CADScor System, which utilizes advanced acoustics and artificial intelligence to provide a rapid diagnosis for patients experiencing chest pain. The system is designed to accurately rule out CAD in under ten minutes, significantly reducing the need for unnecessary invasive procedures and associated costs. Acarix operates in several markets, including Germany, Sweden, and Denmark, and has received both CE marking and DeNovo approval from the FDA for its CADScor System. The company's foundation is rooted in research from Aalborg University, and it has garnered support from various investors and public funding initiatives to advance its innovative solutions in the field of cardiovascular diagnostics.
Action Pharma A/S develops novel drugs for cardio vascular treatment. The company also conducts pre-clinical and early clinical trials of new pharmaceutical products and treatment concepts for cardiovascular, inflammatory, and acquired metabolic diseases. Its products include COMPOUND AP1189, an oral anti-inflammatory compound under development for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and COMPOUND AP405, a modified MSH peptide analogue under development for the treatment of inflammatory skin diseases, such as atopic dermatitis. Action Pharma A/S was founded in 2000 and is based in Aarhus, Denmark.
Biomonitor, founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen, specializes in pharmaceutical development services. The company leverages Professor Bendtzen's extensive research experience in inflammation and immunology, particularly his discoveries related to patient responses to biopharmaceuticals. It has been established that some patients develop antibodies against the proteins and peptides used in these treatments, which can hinder their efficacy. Consequently, Biomonitor focuses on creating methods to monitor these biopharmaceuticals, ensuring that patients receive optimal therapeutic benefits. Since its inception, the company has experienced significant growth, reflecting its commitment to improving patient care in chronic disease management.
Action Pharma A/S develops novel drugs for cardio vascular treatment. The company also conducts pre-clinical and early clinical trials of new pharmaceutical products and treatment concepts for cardiovascular, inflammatory, and acquired metabolic diseases. Its products include COMPOUND AP1189, an oral anti-inflammatory compound under development for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and COMPOUND AP405, a modified MSH peptide analogue under development for the treatment of inflammatory skin diseases, such as atopic dermatitis. Action Pharma A/S was founded in 2000 and is based in Aarhus, Denmark.
**World's largest library of user generated, shareable analytics apps** youcalc let's business people create and share custom reports and analytics on data from SaaS systems — zero coding required! A user driven library of now more than 130 analytics apps for CRM, sales, marketing, service/support and project management, and live data connection to a growing number of SaaS systems (Salesforce.com, Basecamp, AdWords, Google Analytics, Highrise CRM, MailChimp, etc.) **User driven innovation and collaboration** The reporting needs of e.g. sales people are different, but a sales guy in New York may share "custom needs" with a sales guy in another company in Rome. youcalc's mission is to create the world's largest library of analytics apps by allowing business users to create and share analytics apps. All apps built on youcalc become public from the app library, for anyone to use as is or customize to individual needs. All customized apps go back into the app library for the benefit of other users. youcalc let's business users across the world search and use a vast library of analytics apps built by other users with similar needs. **Run anywhere - in iGoogle, inside e.g. Salesforce.com, on intranets, on iPhones, etc.** youcalc apps are easy-to-use, interactive, Flash charts that run anywhere - built for business users, not for expert analysts! Stop spending hours clicking through expert analytics interfaces. Business users get the exact analysis they need, with one click, anywhere they want. Add several apps to iGoogle and you have a personal portal for reporting across all your SaaS systems.
Santaris Pharma A/S is a clinical-stage biopharmaceutical company specializing in RNA-targeted therapies. Founded in 2003 and headquartered in Denmark, the company utilizes its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine to develop single-stranded LNA-based drug candidates for various diseases. Its research focuses on infectious diseases and cardiometabolic disorders, while also addressing cancer, cardiovascular diseases, inflammatory diseases, and rare genetic disorders through collaborations with major pharmaceutical firms. Santaris Pharma has established partnerships with organizations such as miRagen Therapeutics, Shire, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. The company holds exclusive worldwide rights to manufacture and sell products containing LNA as an active ingredient, which supports its goal of obtaining marketing approval for its innovative therapies.
Issuu, Inc. is a digital publishing and discovery platform founded in 2006 in Copenhagen, Denmark. It provides a range of solutions that allow users to create, publish, and share digital publications such as magazines, catalogs, and corporate literature. The platform hosts over 17 million publications and attracts more than 80 million active readers monthly, delivering approximately 5.5 billion page views. Issuu's offerings include tools for custom viewer themes, API integrations for managing content, and monetization solutions through Issuu Story Cloud. The platform is designed to enhance the reading experience by transforming PDFs and images into visually appealing formats accessible across various devices and social media. With additional offices in Palo Alto, California, and Berlin, Germany, Issuu serves a diverse audience, including designers, developers, publishers, and advertisers, ultimately aiming to democratize the publishing experience while preserving the essence of print media.
**World's largest library of user generated, shareable analytics apps** youcalc let's business people create and share custom reports and analytics on data from SaaS systems — zero coding required! A user driven library of now more than 130 analytics apps for CRM, sales, marketing, service/support and project management, and live data connection to a growing number of SaaS systems (Salesforce.com, Basecamp, AdWords, Google Analytics, Highrise CRM, MailChimp, etc.) **User driven innovation and collaboration** The reporting needs of e.g. sales people are different, but a sales guy in New York may share "custom needs" with a sales guy in another company in Rome. youcalc's mission is to create the world's largest library of analytics apps by allowing business users to create and share analytics apps. All apps built on youcalc become public from the app library, for anyone to use as is or customize to individual needs. All customized apps go back into the app library for the benefit of other users. youcalc let's business users across the world search and use a vast library of analytics apps built by other users with similar needs. **Run anywhere - in iGoogle, inside e.g. Salesforce.com, on intranets, on iPhones, etc.** youcalc apps are easy-to-use, interactive, Flash charts that run anywhere - built for business users, not for expert analysts! Stop spending hours clicking through expert analytics interfaces. Business users get the exact analysis they need, with one click, anywhere they want. Add several apps to iGoogle and you have a personal portal for reporting across all your SaaS systems.